Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

LABA

This page shows the latest LABA news and features for those working in and with pharma, biotech and healthcare.

AZ’s COPD triple data sets up market clash with GSK

AZ’s COPD triple data sets up market clash with GSK

AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol, LAMA 

Latest news

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    moderate to severe COPD who are not adequately treated by the combination of an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA). ... The same indication was approved by the FDA in September, and makes Trelegy the first drug on the

  • With US approval, GSK now needs rapid uptake for COPD triple With US approval, GSK now needs rapid uptake for COPD triple

    The three-drug product delivers a long-acting beta agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS) from a single device, and is the first product

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The new product adds long-acting muscarinic receptor antagonist (LAMA) umeclidinium to the ICS/LABA combination, which has proved so successful in GSK's big-selling Advair/Seretide (fluticasone propionate/salmeterol) ... The benefits of Trelegy/Elebrato -

  • GSK preps COPD filing for asthma pioneer Nucala GSK preps COPD filing for asthma pioneer Nucala

    agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium – and shingles vaccine Shingrix which is up for an FDA advisory committee meeting later today.

  • Chiesi Group's Trimbow wins European licence Chiesi Group's Trimbow wins European licence

    The treatment comprises an inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) in one inhaler and is the such triple combination COPD therapy to be ... Administered twice daily at a fixed dose,

More from news
Approximately 3 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

  • Pharma deals during June 2013 Pharma deals during June 2013

    Currently in phase III clinical development for COPD, this combination of a long acting beta-2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Raising Awareness: It’s World COPD Day today!

    If the patient’ s symptoms are not completely controlled with bronchodilators alone, ICS may be recommended in combination with a long-acting bronchodilator (LABA). ... If the patient has had exacerbations but is clinically stable then ICS can be

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Quick links

Infographics

Multimedia